Cite
HARVARD Citation
Mease, P. et al. (n.d.). FRI0512 Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (156-week) improvements in basdai in psoriatic arthritis patients: pooled results from 3 phase iii, randomized, controlled trials. Annals of the rheumatic diseases. pp. 683-684. [Online].